Menu
Search
|

Menu

Close
X

Sellas Life Sciences Group Inc SLS.OQ (NASDAQ Stock Exchange Capital Market)

1.33 USD
-0.02 (-1.48%)
As of 11:32 AM EDT
chart
Previous Close 1.35
Open 1.35
Volume 19,660
3m Avg Volume 87,322
Today’s High 1.35
Today’s Low 1.32
52 Week High 11.08
52 Week Low 0.80
Shares Outstanding (mil) 22.03
Market Capitalization (mil) 29.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-3.469
FY17
-11.894
FY16
-32.495
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
41.05
Price to Sales (TTM)
vs sector
--
8.91
Price to Book (MRQ)
vs sector
1.50
4.65
Price to Cash Flow (TTM)
vs sector
--
28.95
Total Debt to Equity (MRQ)
vs sector
0.41
17.48
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-93.76
12.19
Return on Equity (TTM)
vs sector
-222.28
13.29

EXECUTIVE LEADERSHIP

Angelos Stergiou
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Nicholas Sarlis
Chief Medical Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
John Burns
Principal Accounting Officer, Vice President - Finance, Controller, Since 2018
Salary: --
Bonus: --
David Scheinberg
Director, Since 2017
Salary: --
Bonus: --
Stephen Ghighlieri
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

15 W 38th St Fl 10
NEW YORK   NY   10018-5501

Phone: +1917.4384353

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

SPONSORED STORIES